Work

Metformin Demonstrates Efficacy in Overcoming Cisplatin Resistance Within Triple-negative Breast Cancer Cells by Specifically Targeting Rad51

Year: 2024

Type: article

Abstract: Breast cancer, the most common disease in women worldwide, poses several difficulties, especially when it comes to triple-negative breast cancer (TNBC), which is defined by the lack of certain receptors. The RAD51 gene family, vital for DNA maintenance, is implicated in cancer, including TNBC. Cisplatin, a potent anticancer drug, often loses effectiveness due to resistance mechanisms. Metformin, a diabetes medication, has shown promise in breast cancer treatment. This study investigates their combined impact on TNBC

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.13784591

Author: Dr. Dhivya Prasath Palani Appan, Ann Jency A, Preethi Bala D, Priyadharsini R, Subhalakshmi M

Language: English

Topic: Metabolism, Diabetes, and Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6930152531

FWCI:

Cites:

Cited by:

Related to: